{"schema_version":"secwatch.filing_event.v1","accession":"0001856725-26-000003","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2026-06-29T22:54:48+00:00","discovered_at":"2026-06-30T10:05:00.223008+00:00","generated_at":"2026-06-30T10:05:31.210546+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rani Therapeutics appoints Nicholas Maestas as CFO, approves 2026 Equity Inducement Plan","bullets":["Nicholas Maestas appointed CFO effective June 29, 2026, succeeding Svai Sanford.","Maestas previously CFO of Tempest Therapeutics; base salary $500,000, target bonus 75%.","Maestas receives inducement option for 2,000,000 shares vesting over 4 years.","Board approved 2026 Equity Inducement Plan reserving 5,500,000 shares for new hires.","Plan allows inducement grants under Nasdaq Rule 5635(c)(4) without stockholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001856725-26-000003","json":"https://secwatch.observer/filing/0001856725-26-000003.json","markdown":"https://secwatch.observer/filing/0001856725-26-000003.md","text":"https://secwatch.observer/filing/0001856725-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000185672526000003/0001856725-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000185672526000003/rani-20260624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T10:05:31.210546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}